R.PR
REGISTERED-PRINCIPAL REGISTER
01/03/2022
Voltar para busca
Dado oficial do USPTO
CSL BEHRING
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
CSL BEHRING
ST13
US500000088675262Classe
5, 9, 10, 16, 35, 40, 41, 42, 44
Pedido
88675262
Registro
6655943
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
16/04/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 10, 16, 35, 40, 41, 42, 44
Data de depósito
31/10/2019
Data de registro
01/03/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/03/2022
Última transação
16/04/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
4
Tipo de titular
16
Localização do titular
King of Prussia, PA
Examinador
JENKINS JR, CHARLES
Unidade examinadora
M30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
CSL Behring LLC
Representantes
Scott D. Woldow SMITH, GAMBRELL & RUSSELL, LLP
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 10Classe 16Classe 35Classe 40Classe 41Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for blood diseasesillnesses and conditions; Pharmaceutical preparations for the treatment or prevention of blood and bleeding disorders; diagnostic preparation for medicinal purposes
Classe 9
Electronic publicationsnewsletters and manuals featuring medical information and health treatment information recorded on computer media; Downloadable educational course materials in the field of health and medical treatment
Classe 10
Apparatus of blood analysis; blood testing apparatus
Classe 16
Printed matterprinted periodicalsnewslettersbrochures all in the fields of healthmedicine and pharmaceuticals; publicationshand-outs in the fields of healthmedicinetreatment and pharmaceuticals; Printed instructionaleducationalteaching materials in the field of healthmedicinepharmaceuticals and treatment; Informational flyers featuring healthmedicinepharmaceuticals and treatment information; Brochures about healthmedicinepharmaceuticals and treatment; Pamphlets in the field of healthmedicinepharmaceuticals and treatment information; posters; instruction sheets in the field of healthmedicinepharmaceuticals and treatment; Printed instructionaleducationalteaching materials in the field of healthmedicinepharmaceuticals and treatment
Classe 35
Provision of information relating to wholesale and retail services in the pharmaceutical industry; Provision of information relating to promotion services in the field of promoting awareness of blood diseasesillnesses and conditions and treatment or prevention of blood and bleeding disorderspromoting awareness of pharmaceutical and health treatments
Classe 40
Treatment of biological productscustom manufacturing and fractionation of blood; Processing of human blood plasmaremoving whole blood and separating red blood cells from plasma; treatment of biological productscustom manufacturing and fractionation of blood; production of reagents for immunohaematology laboratories for scientific or medical research use; processing of human blood plasmaremoving whole blood and separating red blood cells from plasma; treatment of human blood and plasma; custom manufacturing of human blood and plasma
Classe 41
Education servicesproviding classesseminarsworkshops in the field of continuing medical education and health education; Educational servicesproviding online instruction in the field of healthmedicinepharmaceuticals and medical treatment via an online website; Electronic publicationsnewsletters in the field of healthmedicinepharmaceuticals and treatment
Classe 42
Scientific and technological researchscientific testing and screening servicestesting of human blood plasma for safety and quality; research and development of scientificmedicalpharmaceutical and blood products; Product research and development services; Laboratory analysismedical laboratory services and scientific laboratory services; Laboratory research services relating to pharmaceuticals; management of scientific research projectsconducting scientific research; Pharmaceutical research services; scientific testing and screening servicestesting of human blood plasma for safety and quality; medical laboratory services regarding human blood plasma
Classe 44
Medical information services; health care information services; medical diagnostic testingmonitoring and reporting services; patient support servicesproviding information to patients in the field of administering medications; medical information concerning pharmaceuticalsmedical products and blood products; Medical testing for diagnostic or treatment purposes; medical testing of human blood plasma; collectionprocessing and testing of human blood and plasma for medical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
14/12/2021
PUBO
PUBLISHED FOR OPPOSITION
14/12/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
24/11/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/11/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
03/11/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/11/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
03/11/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/11/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/11/2021
GNRT
NON-FINAL ACTION E-MAILED
03/11/2021
CNRT
NON-FINAL ACTION WRITTEN
03/11/2021
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
01/10/2021
PBMR
WITHDRAWN FROM PUB - MANAGING ATTORNEY REQUEST
01/10/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/09/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
27/09/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/09/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
20/09/2021
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
13/05/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
13/05/2021
CNSI
SUSPENSION INQUIRY WRITTEN
13/05/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
13/10/2020
GNSL
LETTER OF SUSPENSION E-MAILED
13/10/2020
CNSL
SUSPENSION LETTER WRITTEN
13/10/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/09/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/09/2020
ALIE
ASSIGNED TO LIE
03/09/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/08/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
13/02/2020
GNRT
NON-FINAL ACTION E-MAILED
13/02/2020
CNRT
NON-FINAL ACTION WRITTEN
13/02/2020
DOCK
ASSIGNED TO EXAMINER
05/02/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/11/2019
NWAP
NEW APPLICATION ENTERED
04/11/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CSL BEHRING ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.